MInT-Follow-Up Study
Follow-Up Observational Study of the Randomised Intergroup (MinT) Trial of First Line Treatment for Young Good-Prognosis Patients with Diffuse Large B-Cell Non-Hodgkin’s Lymphoma with a CHOP-like Chemotherapy Regimen with or without the anti-CD20 Antibody Rituximab (IDEC-C2B8).
Organisational structure
Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Steering committee
- Intergroup Principal Investigator: M. Pfreundschuh, Homburg Germany
- Co-ordinating Statistician: M. Loeffler, Leipzig Germany